4901.T
Latest Trade
6,132.00JPYChange
0.00(0.00%)Volume
1,741,600Today's Range
-
6,176.0052 Week Range
-
6,420.00As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 6,132.00 |
|---|---|
Open | 6,154.00 |
Volume | 1,741,600 |
3M AVG Volume | 38.45 |
Today's High | 6,176.00 |
Today's Low | 6,110.00 |
52 Week High | 6,420.00 |
52 Week Low | 4,152.00 |
Shares Out (MIL) | 399.77 |
Market Cap (MIL) | 3,155,685.00 |
Forward P/E | 18.55 |
Dividend (Yield %) | 1.55 |
Lonza Announces Collaboration With Fujifilm Cellular Dynamics
Dr. Reddy's Prices COVID-19 Drug Avigan (Favipiravir) at 99 Rupees/Tablet
Fujifilm Says Delay In Completion Schedule For Acquisition Of Diagnostic Imaging-Related Business From Hitachi
FUJIFILM Holdings Corporation is a Japan-based holding company engaged in the business related to photography, medical care & printing & liquid crystal display materials and copying machines. The Company operates in three business segments. Imaging Solutions segment develops, manufactures and sells color films, digital cameras, color paper services for photographic prints, instant printing equipment and optical devices mainly for general consumers. Healthcare & Materials Solutions segment provides medical system equipment, cosmetics and supplements, pharmaceutical products, biopharmaceutical manufacturing development contract, regenerative medicine products, chemical products, graphic system equipment, inkjet equipment, display materials, recording media and electronic materials for commercial use. Document Solutions segment provides digital multi-functional peripherals, publishing systems, document management software and related solution services mainly for commercial use.
Industry
Medical Equipment & Supplies
Contact Info
Midtown West, 9-7-3, Akasaka
MINATO-KU, TKY
107-0052
Japan
+81.3.62711111
https://www.fujifilmholdings.com/ja/Executive Leadership
Shigetaka Komori
Chairman of the Board, Group Chief Executive Officer, Chairman of Subsidiaries, Representative Director
Kenji Sukeno
President, Group Chief Operating Officer, President of Subsidiary, Representative Director
Koichi Tamai
Vice President, President of Subsidiary, Director
Chisato Yoshizawa
Executive Officer, Director of Human Resources
Takashi Iwasaki
Executive Officer, Chief Technical Officer, Director of Technology Business, Director
Price To Earnings (TTM) | 18.92 |
|---|---|
Price To Sales (TTM) | 1.45 |
Price To Book (MRQ) | 1.22 |
Price To Cash Flow (TTM) | 12.25 |
Total Debt To Equity (MRQ) | 28.09 |
LT Debt To Equity (MRQ) | 24.47 |
Return on Investment (TTM) | 5.14 |
Return on Equity (TTM) | 3.99 |
Fujifilm Holdings Corp said on Wednesday it will invest $2 billion to establish new large-scale cell culture production site in the United States.
The Japanese Health Ministry said on Monday its medical review board concluded that clinical trial data to determine the efficacy of Fujifilm Holdings Corp's COVID-19 drug candidate Avigan is inconclusive.
Japanese health authorities say it is difficult to determine the efficacy of Fujifilm Holdings Corp's antiviral drug Avigan as a treatment for COVID-19, Kyodo News reported on Thursday.
Japanese health authorities say it is difficult to determine the efficacy of Fujifilm Holdings Corp's antiviral drug Avigan as a treatment for COVID-19, Kyodo News reported on Thursday.
Japan's Fujifilm Holdings Corp <4901.T> said on Thursday it has partnered with Shanghai-based Carelink Pharmaceutical Co to seek approval in China for Avigan to treat COVID-19 and influenza.
Fujifilm Holdings Corp said on Friday it was seeking approval for its flu drug Avigan as a treatment for COVID-19 in Japan, a move that comes after a late-stage study showed reduced recovery time for patients with non-severe symptoms.
Fujifilm Holdings Corp said on Friday it had applied for approval in Japan of its anti-influenza drug Avigan as a treatment for COVID-19.
Eli Lilly and Co <LLY.N> said on Thursday it had entered into an agreement with the Bill & Melinda Gates Foundation for potential supply of its experimental antibody treatments for COVID-19 to low and middle-income countries.
Fujifilm Holdings Corp <4901.T> said on Thursday that it had signed a manufacturing contract agreement with U.S.-based firm VLP Therapeutics for a COVID-19 vaccine formulation.
Fujifilm Holdings Corp said on Thursday it concluded a manufacturing contract agreement with VLP Therapeutics for a COVID-19 vaccine formulation.
Fujifilm Holdings Corp said on Wednesday a late-stage study of its antiviral drug Avigan showed it reduced recovery times for COVID-19 patients with non-severe symptoms, boosting expectations for regulatory approval in Japan.
Philippine scientists were set on Wednesday to meet representatives of the Russian state research facility that developed a coronavirus vaccine, to discuss participation in clinical trials and access to its research data.
The United States has awarded a $265 million contract to a Texas facility of Japan's Fujifilm Holdings Corp to step up production of a coronavirus vaccine candidate, President Donald Trump said.
Japan's Fujifilm Holdings Corp announced a deal with India's Dr Reddy's Laboratories and Dubai-based Global Response Aid (GRA) to sell its anti-flu drug Avigan for COVID-19 treatment globally excluding Japan, China and Russia.
Fujifilm Holdings Corp said on Wednesday it was partnering with Dr Reddy's Laboratories to sell the anti-flu drug Avigan in India and elsewhere to treat COVID-19, the respiratory disease caused by the coronavirus.
(This June 10 story corrects second paragraph to say facility makes antibody drugs, not viral vaccines)
* TONIX PHARMACEUTICALS ANNOUNCES FUJIFILM DIOSYNTH BIOTECHNOLOGIES TO BE MANUFACTURING PARTNER FOR COVID-19 VACCINE CANDIDATE TNX-1800 Source text for Eikon: Further company coverage:
Shares of Fujifilm Holdings Corp fell on Wednesday after Kyodo news reported that so far there has been no clear evidence of efficacy for its drug Avigan in treating the novel coronavirus in some clinical trials.
Shares of Fujifilm Holdings Corp <4901.T> fell on Wednesday after Kyodo news reported that so far there has been no clear evidence of efficacy for its drug Avigan in treating the novel coronavirus in some clinical trials.
* FUJIFILM'S ANTI-FLU AVIGAN NOT SHOWING APPARENT EFFICACY IN CORONAVIRUS TREATMENT - KYODO NEWS, CITING SOURCES Source text : https://bit.ly/3bIfDVP
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.